AUTHOR=Lawler Thomas , Parlato Lisa , Warren Andersen Shaneda 

TITLE=The histological and molecular characteristics of early-onset colorectal cancer: a systematic review and meta-analysis

JOURNAL=Frontiers in Oncology

VOLUME=14

YEAR=2024

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1349572

DOI=10.3389/fonc.2024.1349572

ISSN=2234-943X

ABSTRACT=<sec><title>Background</title><p>Early-onset colorectal cancer (CRC), defined as diagnosis before age 50, has increased in recent decades. Although more often diagnosed at advanced stage, associations with other histological and molecular markers that impact prognosis and treatment remain to be clarified. We conducted a systematic review and meta-analysis concerning the prevalence of prognostic and predictive tumor markers for early- vs. late-onset CRC, including oncogene mutations, microsatellite instability (MSI), and emerging markers including immune cells and the consensus molecular subtypes.</p></sec><sec><title>Methods</title><p>We systematically searched PubMed for original research articles published between April 2013–January 2024. Included studies compared the prevalence of tumor markers in early- vs. late-onset CRC. A meta-analysis was completed and summary odds ratios (ORs) with 95% confidence intervals (CIs) were obtained from a random effects model via inverse variance weighting. A sensitivity analysis was completed to restrict the meta-analysis to studies that excluded individuals with Lynch syndrome, a hereditary condition that influences the distribution of tumor markers for early-onset CRC.</p></sec><sec><title>Results</title><p>In total, 149 articles were identified. Tumors from early-onset CRC are less likely to include mutations in <italic>KRAS</italic> (OR, 95% CI: 0.91, 0.85-0.98), <italic>BRAF</italic> (0.63, 0.51-0.78), <italic>APC</italic> (0.70, 0.58-0.84), and <italic>NRAS</italic> (0.88, 0.78-1.00) but more likely to include mutations in <italic>PTEN</italic> (1.68, 1.04-2.73) and <italic>TP53</italic> (1.34, 1.24-1.45). After limiting to studies that excluded Lynch syndrome, the associations between early-onset CRC and <italic>BRAF</italic> (0.77, 0.64-0.92) and <italic>APC</italic> mutation (0.81, 0.67-0.97) were attenuated, while an inverse association with <italic>PIK3CA</italic> mutation was also observed (0.88, 0.78-0.99). Early-onset tumors are less likely to develop along the CpG Island Methylator Phenotype pathway (0.24, 0.10-0.57), but more likely to possess adverse histological features including high tumor grade (1.20, 1.15-1.25), and mucinous (1.22, 1.16-1.27) or signet ring histology (2.32, 2.08-2.57). A positive association with MSI status (1.31, 1.11-1.56) was also identified. Associations with immune markers and the consensus molecular subtypes are inconsistent.</p></sec><sec><title>Discussion</title><p>A lower prevalence of mutations in <italic>KRAS</italic> and <italic>BRAF</italic> is consistent with extended survival and superior response to targeted therapies for metastatic disease. Conversely, early-onset CRC is associated with aggressive histological subtypes and <italic>TP53</italic> and <italic>PTEN</italic> mutations, which may serve as therapeutic targets.</p></sec>